1 / 18

Familial Hypercholesterolaemia: LIPOchip ® experience

Familial Hypercholesterolaemia: LIPOchip ® experience . Laura Yarram Bristol Genetics Laboratory. Image 1. Achilles tendon xanthoma. Image 2. Xanthelasma (Image from Pietroleonardo & Ruzicka, 2009). What is FH?. Autosomal Dominant 1/500 heterozygotes in UK

ginger
Download Presentation

Familial Hypercholesterolaemia: LIPOchip ® experience

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Bristol Genetics Laboratory Familial Hypercholesterolaemia: LIPOchip® experience Laura Yarram Bristol Genetics Laboratory

  2. Image 1. Achilles tendon xanthoma Image 2. Xanthelasma (Image from Pietroleonardo & Ruzicka, 2009) Bristol Genetics Laboratory What is FH? • Autosomal Dominant • 1/500 heterozygotes in UK • (1/1,000,000 compound heterozygotes) • Caused by LDLR, APOB &PCSK9 mutations • Raised cholesterol, Xanthomas/Xanthelasma, Risk of CVD • Simon Broome Criteria • ‘definite’ or ‘possible’ • ‘Normal’ life expectancy on statin treatment • NICE guidelines

  3. Bristol Genetics Laboratory Why Perform Genetic Testing? • Patient A, aged 8 • LDLR mutation confirmed in family • Equivocal cholesterol – 5.6mmol/L (FH >6.7mmol/L in children, ‘Normal’ <4.0mmol/L) • Family history of extensive cardiovascular disease • Great uncle – Myocardial infarction at aged 31 • Patient A – mutation identified • Will start statin treatment at ~ age 10 • Early treatment gives the maximum health benefit • More likely to adhere to treatment

  4. p.[=] + [=] p.[Asp589fs] + [Lys311Thr] p.[Asp589fs] + [=] Bristol Genetics Laboratory Why Perform Genetic Testing? • Patient B, aged 55 • Pre-treatment cholesterol ~20mmol/L (FH >7.5mmol/L in adult) • Unexpected compound heterozygote for two unclassified variants • c.[1766delA] + [932A>C] • p.[Asp589fs] + [Lys311Thr] • Pedigree: • Instigated further cardiology investigations • Exercise ECG positive • Genetic diagnosis allows consideration of LDL apheresis

  5. CASCADE Bristol Genetics Laboratory Current Testing Method • Validated on known positive control samples • Tested 104 samples to date ARMS – 20 common mutations • MLPA (MRC-Holland: P062B) validated using 4 reported samples, obtained from a Norwegian lab +ve -ve Mutation confirmation Sequencing REPORTOffer sequencing/ MLPA REPORT Sequencing +ve -ve REPORT Proceed to MLPA • Primers designed for all 18 LDLR exons + promoter • Sequenced in 17 fragments • Validated using 4 known positives +ve -ve REPORT REPORT

  6. Bristol Genetics Laboratory Simon Broome Audit Data

  7. Bristol Genetics Laboratory Results to Date • 34 pathogenic variants detected to date • + 2 variants ‘likely non-pathogenic’ • c.2390-16G>A and c.969C>T (p.[=]) • 28 of these variants required UV studies (Nb. Most were previously reported to database but with no functional/family studies) Commonly detected mutations in SW diagnostic patients (n=48)

  8. Bristol Genetics Laboratory Assay Sensitivity • Testing strategy not sustainable for disease frequency

  9. Bristol Genetics Laboratory LIPOchip® Background • LIPOchip® has been in development since 2002 to detect the most prevalent Spanish mutations • Current Version (8) includes ‘European’ specific mutations • More than 100 hospitals are using LIPOchip® throughout Europe • Copy number changes also detected • Specific ‘BritChip’ due to be released June/July 2010 • Validation – 40 samples used (36 previously tested, 4 new cases) • Blind test • All results concordant

  10. 1 Amplification 2 Fragmentation 3 Labelling 4 Hybridization 5 Results analysis 0 Extraction PCR mixes 1, 2, 3 and 4 DNAse + Alkaline Phosphatase TdT + Biotin-ddUTP Tecan 4800 HS Pro 3hours and 30 minutes 45 minutes 60 minutes 2 hours 2 hours OVERLAPPING PROCESSES DAY 1 DAY 2 Bristol Genetics Laboratory LIPOchip® Processing

  11. c.429C>A, p.Cys143X c.1432G>A, p.Gly478Arg Mutations not present in FH20 ARMS Bristol Genetics Laboratory Mutations Detected

  12. Bristol Genetics Laboratory c.2093G>A (p.Cys698Tyr) Patient has c.2093G>T (p.Cys698Phe) Slight displacement from the ‘Normal’ group

  13. Bristol Genetics Laboratory Del ex7-3’UTR

  14. MLPA result LIPOchip result 16 17 18 Long-range PCR confirmation Ex16_F Ex18_R ~5kb 3.5kb N dup 17 N 3.5kb Bristol Genetics Laboratory Duplication LDLR Exon 17

  15. Bristol Genetics Laboratory LIPOchip® Trial Results • Point mutation analysis is robust • Copy number detection results not always reportable • MLPA will still be required in a significant proportion of cases

  16. Bristol Genetics Laboratory Proposed Method of Testing • Initial screen using LIPOchip® platform • Current European chip v.8 detects 251 mutations + copy number changes • British LIPOchip predicted to detect 80% of UK mutations • Followed by full bi-directional sequencing of LDLR (and MLPA where necessary) • Negative patients meeting Simon Broome criteria • Full PCSK9 screen by bi-directional sequencing (Validation near completion, 12 fragments) • Sequencing of APOB hotspot regions (exon 26 and 29)

  17. Bristol Genetics Laboratory Conclusion • Comprehensive testing service for FH implemented • 131 cases tested overall, 48% mutation positive • LIPOchip® evaluated – further work required to validate British version on release • Network links with lipid and cardiac specialists have been established across the SW region • Mechanism for robust funding is yet to be established

  18. Bristol Genetics Laboratory Acknowledgments • Bristol Genetics Lab • Maggie Williams • Sarah Burton-Jones • Thalia Antoniadi • Genetic Technologists – Teresa Tovey, Jenny Coles, Gemma Dennis, William Cross and Matthew Garner • Extraction Lab team and Array team • Biochemistry Department, BRI • Graham Bayly • Mathangi Balasubramani • Bath, Weston-super-Mare and Gloucester Biochemistry teams • GOS Lab • Alison Taylor • Progenika • Xabier Abad • Maximilliano Crosetti • Gen-probe (Tepnel diagnostics) • MRC-Holland

More Related